Genetic Disorders

Pharma News for Merck, Ipsen, bluebird bio

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Merck and Moderna Initiate Study to Evaluate V940; FDA Approves Vertex and CRISPR Therapeutics’ CASGEVY for SCD; Novartis Updated on its Investigational Iptacopan Phase III Study; FDA Grants Priority Review for New Drug Application for Elafibranor; FDA Approves bluebird bio’s LYFGENIA for Patients SCD; FDA Fast Track Designation for DMD Gene Therapy

Merck and Moderna Initiate INTerpath-002, a Phase III Study Evaluating V940 in Combination with KEYTRUDA for Adjuvant Treatment of Patients with Certain Types of Resected NSCLC Merck (also known as MSD outside the United States and Canada) and Moderna, Inc. have commenced the INTerpath-002 trial—a crucial Phase III randomized clinical study—to assess V940 (mRNA-4157), an investigational personalized neoantigen therapy (INT), in conjunction with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy for patients with completely removed (R0) Stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC) (including those with nodal involvement [N2]). The global recruitm...

Explore More...

FDA Expands GSK’s Jemperli Approval; Biogen to Acquire Reata Pharma; Enhertu Shows Survival Boost in HER2+ Solid Tumors; FDA Rejects Citius’ Revived IL-2 Therapy; FDA Fast Track designation to IVS-3001 for RCC; EU Orphan Drug Designation to Biohaven’s Taldefgrobep Alfa

Gilead’s Magrolimab Plus Azacitidine for MDS; FDA Approveds VANFLYTA for Newly Diagnosed AML; FDA Awards Fast Track Designation to ARX517 mCRPC; EMA Rejects Mirati’s Krazati; Harmony Phase III Pitolisant Trial for PWS Patients; Belite Bio’s Phase 3 DRAGON Trial of Tinlarebant for STGD

The Future is Here: BioMarin’s Roctavian First Hemophilia A Gene Therapy Paving the Way for a Cure

Duchenne Muscular Dystrophy Market DMD Market

Sarepta’s ELEVIDYS: First Gene Therapy for Duchenne Muscular Dystrophy (DMD) Treatment

Pharma News for Pfizer, Sarepta, FibroGen, Erasca

FDA Approves Jardiance for Type 2 Diabetes; FDA Approves Pfizer’s LITFULO for Alopecia Areata; Sarepta Therapeutics’s ELEVIDYS Approval; Tonix Pharmaceuticals to Acquire Two Migraine Products from Upsher-Smith; FibroGen’s Phase 3 ZEPHYRUS-1 Study of Pamrevlumab; FDA Orphan Drug Designation to ERAS-801 for Malignant Glioma

Gene Therapies for Dystrophic Epidermolysis Bullosa

Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?

Pharma News for Kyverna, Annovis, Astellas, FibroGen

FDA Fast Track Status to Kyverna’s KYV-101; Annovis’s Phase III Study for Buntanetap; Gilteritinib Demonstrated Benefit in AML Patients; FDA Orphan Drug Designation to DTx Pharma’s DTx-1252; FibroGen’s LELANTOS-1 Phase 3 Clinical Study Result

pharma-news-for-bms-teva-biogen-atsena-kiromic

FDA Grants Priority Review to BMS’ Luspatercept; Teva and MedinCell’s Risperidone FDA Approval; Biogens’s QALSODY FDA Accelerated Approval; FDA IND Authorization to Kiromic’s Deltacel; Atsena’s ATSN-201 FDA IND Clearance

Pharma News for XORTX, Roche, Lantheus, Janssen, Daiichi Sankyo, bluebird bio, and POINT Biopharma Global

Janssen’s AKEEGA Approval; FDA Approves Roche’s Polivy Combo for Frontline B-cell Lymphoma; Daiichi Sankyo’s Quizartinib for Adults With FLT3-ITD-Positive AML; bluebird bio BLA for lovo-cel for Patients with Sickle Cell Disease; Fast Track Designation for Lu-PNT2002 for mCRPC Treatment; FDA Orphan Drug Designation to XORTX’s Oxypurinol

Polymerase Chain Reaction Market Outlook and Forecast

Polymerase Chain Reaction (PCR) Market: Evaluating the Major Market Dynamics and Key Trends Driving the Growth

DAYBUE: First and Only Approved Drug for Rett Syndrome Treatment

Pharma news and updates for Roche, Acadia, Shorla Oncology, Calliditas, Mesoblast, Sanofi, Provention Bio

Sanofi to Acquire Provention Bio; USFDA Committee Votes in Favor Roche’s Polivy; FDA to Review Mesoblast’s GvHD Drug; FDA Approves Acadia’s Daybue ; FDA Approves Nelarabine Injection; Calliditas’s Nefecon Trial Reuslt in IgA Nephropathy

Next-Generation Sequencing Market Trends, Development, Key Companies, Applications, and Future

Evaluating the Key Trends and Developments in the Global Next-Generation Sequencing Market

Pharma News and Updates for Actinium, Apellis, Chiesi, IVERIC, Travere, Takeda

Actinium Announces Phase III SIERRA Trial Results; FDA Approves Apellis’s Geographic Atrophy Drug; FDA Gives Green Light to Chiesi’s Lamzede; FDA Accepts NDA and Grants Priority Review for Avacincaptad Pegol; FDA Approves Travere’s Kidney Disorder Drug; Takeda Presents Phase 3 GRAPHITE Study Results

Millions of Patients and Billions in Untapped Androgenetic Alopecia Treatment Market

Latest Pharma News and Updates for BeiGene, Seagen, Alnylam, Roche, Astellas

BeiGene’s Brukinsa Approval; FDA Approval to Seagen’s TUKYSA; NICE Recommends Alnylam’s Amvuttra; FDA Approves Brenzavvy for Type 2 Diabetes; Roche’s Tecentriq to be Filed for Early-stage Liver Cancer; FDA Lifts Hold on Astellas’ Pompe Gene Therapy

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective